A phase 2 clinical trial (NCT04050462) with the anti-CSF1R antibody Cabiralizumab or BMS-986253, an IL-8 inhibitor, in combination with the PD-1 blocker Nivolumab is currently ongoing for advanced HCC patients. The gene discussed is CSF1R; the disease is hepatocellular carcinoma.